Sep. 14 at 3:12 AM
$IXHL $RMD @DougieFreshPicks @JL_TradeZ Two Senior management professionals were part Abbott Laboratories
$ABT are now on
$RMD's board of directors. .
Dr. John Hernandez, a ✨✨ ✨ Current
$RMD Board of Director, was previously the Vice President of global health economics and Outcomes of Research at Abbott
$ABT Laboratories.✨ ✨✨ He served in that position before joining the Board of ResMed
$RMD board of directors.
2 board memberships, with past senior executive roles indicates a long historical connection between the 2 companies through the >>> careers of shared decision making professionals. <<< At AbbVie, Mowad-Nassar led the ✨✨ commercial integration of the
$63 Billion Allergan acquisition, one of Largest in industry History. ✨ ✨ She ensured continuity across product joins
$RMD's board of directors. ✅️
$RMD's Market Cap is 39 Billion dollars ✅️
✨ ✨Mowad-Nassar President of Specialty and U.S. Therapeutics Operations now at AbbVie oversees
$6 billion dollar commercial portfolio spanning more than 17 therapeutic areas and oversees a workforce of 6,000+ with her 30 years of experience . While AbbVie was formerly part of
$ABT, it is a separate company with strong history with
$ABT. ✨ ✨-Nassar joined ResMed's board of directors in August 2025. 🎯 TIA for DD with details about relationships with past Senior management Luminaries of
$ABT joining
$RMD's boards.** Dr. Alison Wimms appointed by
$RMD to represent
$RMD extensive interest with knowledge and collaborating in detail with
$IXHL's phase 3 trials.🎯
